Colchicine Agepha Pharma (colchicine)

Where it stands

Colchicine Agepha Pharma (colchicine) is authorised in the EU. The European Commission granted the marketing authorisation to Agepha Pharma s.r.o. on 2026-07-24, following a positive CHMP opinion on 2026-05-21.

The authorised indication is secondary prevention of atherothrombotic events in adult patients with coronary disease stable for at least 6 months. The records list the therapeutic areas as myocardial infarction, stroke and coronary artery disease. The wording limits use to adults with chronic, stable coronary disease. It does not cover the acute setting or primary prevention.

The interval between opinion and decision was 64 days, which falls within the roughly 67-day period normally allowed for the Commission to issue its decision after a CHMP opinion. The records show no sign of delay or complication.

Regulatory pathway and designations

The records show no designations for this product. There is no orphan, PRIME or similar status, and no accelerated assessment is recorded.

The records do not state the legal basis of the application (for example full, hybrid or well-established use) or whether the authorisation is standard, conditional or under exceptional circumstances. They also do not say whether it is a centralised-procedure product beyond the CHMP and EC milestones shown. Those details would be in the EPAR and the product information once published, and should not be assumed here.

The two milestones follow the normal centralised sequence. The CHMP gave a positive scientific opinion, and the EC then adopted a decision that made the authorisation valid in all EU Member States.

Safety and pharmacovigilance

The records contain no safety data. They include no risk management plan details, contraindications, warnings, additional monitoring status or post-authorisation safety commitments, so no product-specific safety conclusions can be drawn from them.

As a general point, every centrally authorised EU medicine is covered by an EU risk management plan and by routine pharmacovigilance. This includes signal detection and periodic safety reporting. Product-specific obligations are set out in the authorisation conditions and the summary of product characteristics. Professionals should check those documents directly.

What to watch

The first item is publication of the EPAR and the final product information. These should show the legal basis, the assessment rationale, the risk management plan and any conditions attached to the authorisation. The records do not currently provide this.

The second is national implementation. EU authorisation does not by itself mean the product is available or reimbursed in a given country. Launch timing, pricing and reimbursement are decided nationally, and the records say nothing about Agepha Pharma's plans.

The third is how the indication is applied in practice. It is restricted to adults with coronary disease stable for at least 6 months, so prescribing guidance and any later label changes will be the main regulatory signals after approval.